77results about How to "No cytotoxicity" patented technology

The present invention discloses a method for preparing heteroatom doped carbon quantum dot, and application thereof in fields of biomedicine, catalysts, photoelectric devices, etc. The various kinds of heteroatom doped carbon quantum dots are obtained by using a conjugated polymer as a precursor and through a process of high temperature carbonization. These carbon quantum dots contain one or more heteroatoms selected from the group consisting of N, S, Si, Se, P, As, Ge, Gd, B, Sb and Te, the absorption spectrum of which ranges from 300 to 850 nm, and the fluorescence emission wavelength of which is within a range of 350 to 1000 nm. The carbon quantum dot has a broad application prospect in serving as a new type photosensitizer, preparing drugs for photodynamic therapy of cancer and sterilization, photocatalytic degradation of organic pollutants, photocatalytic water-splitting for hydrogen generation, organic polymer solar cell and quantum dot-sensitized solar cell.

The invention discloses a novel chondrocyte epimatrix membrane and a preparation method thereof. The membrane contains cell epimatrix ingredients which have bioactivity and cell activity, wherein the cell epimatrix comprises the following main ingredients in percentage by weight: 80 to 95 percent of bionic type II collagen in an acellular cartilage matrix and 10 to 20 percent of hyaluronic acid, 10 to 20 percent of aminopolysaccharide and the like which serve as a chondrocyte epimatrix; the chondrocyte epimatrix biological membrane prepared from the acellular cartilage matrix has the bionic chondrocyte epimatrix ingredients, is excellent in cell consistency, does not arouse immunological rejection of host cartilage tissue, can be used for repairing the damage of hyaline cartilage tissue of joints and reconstructing the hyaline cartilage tissue, and also can be used for a seed cell inoculating vector and a growth factor sustained-release vector; and the chondrocyte epimatrix contains blood vessel inhibiting factor ingredients, so the membrane also can be used for preventing the conglutination of tissue such as muscle tendons.

The invention discloses a preparation method of calcium phosphate bone cement simultaneously releasing zinc ions and silicate ions. The preparation method comprises the following steps that (1) calcium phosphate bone cement powder, inorganic salt containing zinc ions and inorganic salt containing silicate ions are mixed evenly to obtain the calcium phosphate bone cement containing zinc and silicon elements, namely a solid phase; (2) the solid phase cement obtained through the step (1) and a liquid phase are blended, wherein the mass ratio of the liquid phase volume to the solid phase powder is 0.3-0.6 mL / g. The zinc ions and the silicate ions are simultaneously added into the calcium phosphate bone cement for the first time, the calcium phosphate bone cement has the advantages of having high mechanical strength and appropriate setting time and being capable of continuously releasing the zinc ions and silicate ions for a long time and controllable in release amount, and meanwhile the two different types of released functional ions can play roles of synergistically inhibiting bone absorption and promoting bone repair. Compared with traditional calcium phosphate bone cement, the calcium phosphate bone cement has more excellent bone defect repairing effect and wider clinical application prospect.

The purpose of the invention is to provide capsaicinoid-like substances to be used as food additives and pharmaceutical ingredients. Capsaicinoid-like substances represented by the following general formula:and food and pharmaceutical compositions comprising them.

The embodiment of the invention discloses a method for preparing a tissue engineering frame. The tissue engineering frame is obtained by processing biodegradable polymer fibers in supercritical CO2 and by controlling processing temperature and processing temperature. The supercritical CO2 has certain dissolvent properties and can generate a micro-melting effect on the surfaces of the biodegradable polymer fibers, so when CO2 is discharged by decompression, the molten parts of contacted surfaces of biodegradable polymer fibers are solidified and crosslinked together to form the tissue engineering frame with high mechanical performance. Thus, the preparation method provided by the invention can complete the crosslinking and melting of fibers at a relatively lower temperature without dissolvent, crosslinker and the like, and generates no cytotoxicity.

Biodegradable copolymer hydrogels are provided. The biodegradable copolymer hydrogels have a structure of Formula (I) or Formula (II)A-B—BOX—B-A  Formula (I)B-A-B—(BOX—B-A-B)n-BOX—B-A-B  Formula (II), wherein, A comprises a hydrophilic polyethylene glycol polymer (A); B comprises a hydrophobic polyester polymer (B); BOX is bifunctional group monomer of 2,2′-Bis(2-oxazoline) and used for coupling the blocks A-B or B-A-B; and n is an integer, equal to or greater than 0.

The invention discloses E-configuration benzamide compounds, and a pharmaceutical preparation application thereof. The structure of the E-configuration benzamide compounds is disclosed as Formula (I); the chemical name is N-(2-amino-4-fluorophenyl)-4-[N-[(E)-3-(3-pyridyl)acryloyl]aminomethyl]benzamide; and in the structural formula, the configuration of the 3-pyridylacryloyl group is E. The E-configuration benzamide compounds disclosed as Formula (I) have subtype selective histone deacetylase inhibition activity, and are mainly used for inhibiting HDAC1, HDAC2 and HDAC3 in Class I HDAC and HDAC10 in Class IIb HDAC. The E-configuration benzamide compounds disclosed as Formula (I) can be used for treating diseases related to histone deacetylase activity abnormity, such as cancers, including lymphomata, entity tumor, blood system tumors and the like.

The invention discloses a hydrogen sulfide slow-release dressing and a manufacturing method thereof. The hydrogen sulfide sustained-release dressing comprises a hydrocolloid, a surfactant and sodium hydrosulfide. By adjusting the proportion of the hydrophilic polymer in the hydrocolloid and the surfactant, the hydrocolloid can have different water absorption rates, and further the sodium hydrosulfide coated in the hydrocolloid has different hydrogen sulfide release rates along with the water absorption rates. The hydrogen sulfide slow-release dressing can slowly release hydrogen sulfide without generating cytotoxicity, so that healing of chronic wounds can be effectively promoted.

The present invention provides a bacillus sp. having a deposit access number of CGMCC NO. 5744 and a hyaluronidase produced by the bacillus and the amino acid sequence of the hyaluronidase is shown in SEQ ID NO: 2. The present invention further relates to a process for preparing oligomeric hyaluronic acid or salts thereof or low-molecular-weight hyaluronic acid or salts thereof by using the bacillus or the hyaluronidase produced thereby. The produced oligomeric hyaluronates or low-molecular-weight hyaluronates have advantages such as good transdermal absorption ability, high purity, no cytotoxicity, potent antioxidant ability. The present invention also provides use of the bacillus having a deposit access number of CGMCC NO. 5744, or the hyaluronidase, oligomeric hyaluronates or salts thereof, low-molecular-weight hyaluronates or salts thereof produced by the bacillus in the fields of osmetics, food products and medicines.

The present invention relates to a method of localizing an intact immunoglobulin-format antibody in cytosol by permeating membrane of cells. The present invention also relates to a light-chain variable region (VL) that induces an intact immunoglobulin-format antibody to penetrate the membrane of living cells and be localized in the cytosol, and to an antibody comprising the same. The present invention also relates to a biologically active molecule fused to the antibody and selected from the group consisting of peptides, proteins, small-molecule drugs, nanoparticles and liposomes. The present invention also relates to a composition for prevention, treatment or diagnosis of cancer, comprising: the antibody; or a biological active molecule fused to the antibody and selected from the group consisting of peptides, proteins, small-molecule drugs, nanoparticles and liposomes. The present invention also relates to a polynucleotide that encodes the light-chain variable region and the antibody. The present invention also relates to a method for producing an antibody which penetrates cells and is localized in the cytosol.According to the method of the present invention, which allows an intact immunoglobulin-format antibody to actively penetrate living cells and be localized in the cytosol, the antibody can penetrate living cells and be localized in the cytosol, without having to use a special external protein delivery system. Moreover, the use of the cytosol-penetrating light-chain variable region according to the present invention and the intact immunoglobulin-format antibody comprising the same can penetrate cells and remain in the cytosol, without affecting the high specificity and affinity of a human antibody heavy-chain variable region (VH) for antigens, and thus can be localized in the cytosol which is currently classified as a target in disease treatment based on small-molecule drugs, and at the same time, can exhibit high effects on the treatment and diagnosis of tumor and disease-related factors that show structurally complex interactions through a wide and flat surface between protein and protein. In addition, these can selectively inhibit KRas mutants, which are major drug resistance-associated factors in the use of various conventional tumor therapeutic agents, and at the same time, can be used in combination with conventional therapeutic agents to thereby exhibit effective anticancer activity.

(Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for Solving Problems)The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

The present invention relates to a method for inhibiting intracellular activated RAS using an intact immunoglobulin-type antibody having the ability to penetrate the cytosol. The present invention also relates to a heavy-chain variable region (VH) which induces an intact immunoglobulin-type antibody to actively penetrate the cytosol of living cells through endocytosis and endosomal escape and to bind to activated RAS in the cytosol, and to an antibody comprising the same. The present invention also relates to a method of inhibiting the growth of cancer or tumor cells and a method of treating cancer or tumor, by use of the antibody. The present invention also relates to a method for screening a heavy-chain variable region that binds specifically to RAS in the cytosol. The present invention also relates to a biologically active molecule fused to the antibody and selected from the group consisting of peptides, proteins, small-molecule drugs, nanoparticles and liposomes. The present invention also relates to a composition for prevention, treatment or diagnosis of cancer, comprising: the antibody; or a biological active molecule fused to the antibody and selected from the group consisting of peptides, proteins, small-molecule drugs, nanoparticles and liposomes. The present invention also relates to a polynucleotide that encodes the light-chain variable region and the antibody.According to the present invention, the method for inhibiting intracellular activated RAS using an intact immunoglobulin-type antibody having the ability to penetrate the cytosol is achieved by allowing the antibody to penetrate living cells and to specifically recognize activated (GTP-bound) RAS in the cytosol. Thus, the antibody can target activated (GTP-bound) RAS in the cytosol of living cells and inhibit the activity of the RAS.Furthermore, the antibody light-chain variable region according to the present invention and an antibody comprising the same is able to penetrate living cells and localize in the cytosol, without having to use a special external protein delivery system. Particularly, the antibody light-chain variable region according to the present invention can easily interact with various human heavy-chain variable regions (VHs) and has the ability to penetrate the cytosol and remain in the cytosol, and an intact IgG-type monoclonal antibody comprising the light-chain variable region can penetrate cells and localize in the cytosol, and shows no cytotoxicity non-specific for target cells.The antibody heavy-chain variable region according to the present invention and an antibody comprising the same can selectively inhibit mutations of the major drug resistance-related factor RAS of conventional various tumor therapeutic agents, and can exhibit synergistic anticancer activity with conventional therapeutic agents. In addition, the cytosol-penetrating, intact immunoglobulin-type antibody according to the present invention can penetrate cells and remain in the cytosol, without affecting the high specificity and affinity of a human antibody heavy-chain variable region (VH) for antigens, and thus can localize in the cytosol which is currently classified as a target in disease treatment based on small-molecule drugs, and at the same time, can exhibit high effects on the treatment and diagnosis of tumor and disease-related factors that show structurally complex interactions through a wide and flat surface between protein and protein.

The present invention relates to a contrast agent for nuclear magnetic resonance imaging, and more particularly, to a contrast agent for nuclear magnetic resonance imaging containing melanin nanoparticles having a uniform shape and size, thereby providing good dispersibility in water, no cell toxicity, and a long retention time in vivo.

This invention is for the compound containing ginsenoside Rg3 as an active ingredient to prevent and treat Hepatitis C virus infection. Specifically, the ginsenoside Rg3 of this invention demonstrated the predominant antiviral activities and apotosis actions in a dose-dependent manner in the Hepatitis C virus infected cells (Huh 7.5.1). Confirmed that it reduces the levels of TNF-α and thioredoxin significantly, and increases phospho-NFκB. It also demonstrated same effectiveness as PegInterferone alpha-2b(PegIFN a-2b, Hepatitis C therapeutics), and has no cytotoxicity to human bodies. Thus, it may be used safely as an active ingredient of medical / pharmaceutical and health food compounds for preventing or treating Hepatitis C.

The invention relates to a Brachymystax lenok Cathelicidin antimicrobial peptide CATH_BARLE, and a gene, a preparation and an application thereof, and belongs to the technical field of biomedicine. The gene of the CATH_BARLE is composed of 909 nucleotides, and a part coding the mature peptide is nucleotides from the 439th bit to the 597th bit. The mature peptide CATH_BARLE is rich in alkaline amino acids, and has a strong bactericidal effect on common pathogens in aquatic product culture. The CATH_BARLE has a simple structure, does not contain a disulfide bond or an annular structure, and is convenient for chemical synthesis and gene engineering preparation; and the CATH_BARLE also has a good killing effect on many clinical drug-resistant bacteria, especially fungi.

The invention relates to imidazolone-morphinan and an application thereof. A research result indicates that imidazolone-morphinan has anti-inflammatory activity in an inhibition model experiment for inflammatory factors released by LPS (lipopolysaccharide) activated microglia BV2, does not show up cytotoxicity, is expected to be a candidate drug for prophylactic treatment of Parkinson's disease and has good development prospect.

The invention provides a compound, a nano super-molecular drug carrier and a drug containing the nano super-molecular drug carrier and belongs to the technical field of nano super-molecular materials.The compound and modified polyethylene glycol are co-assembled to form the nano super-molecular drug carrier and the loading of an anionic photosensitizer is realized; the photosensitizer can be specifically released at a tumor part and targeted imaging and treatment of a solid tumor are realized. The compound is 5,11,17,23,29-pentaguanidyl-31,32,33,34,35-pentaalkoxycalix[5]arene with a specificstructure. The nano super-molecular drug carrier takes the compound with a structural formula shown as a formula (I) and the modified polyethylene glycol as building units. The drug comprises the nanosuper-molecular drug carrier and the anionic photosensitizer loaded on the nano super-molecular drug carrier.

A CO2-type microbubble reagent for the ultrasonic induced blocking of blood vessel in tumor region and the fat decreasement for beautifying face is composed of the macro-molecular carrier and the microbubble reagent prepared from Co2 gas or the organic acid plus NaHCO3.

The invention relates to a preparation method of a poly hydroxybutyrate caproic-acid copolyester tissue engineering scaffold. The preparation method comprises the steps that after 25-40% of poly hydroxybutyrate caproic-acid copolyester, 30-45% of polyoxyethylene and 25-40% of sodium bicarbonate are prepared into a mixed solution, spinning is performed to obtain poly hydroxybutyrate caproic-acid copolyester nanofiber, the nanofiber is processed in supercritical CO2, an intermediate product is prepared by controlling the processing pressure and processing temperature, the obtained intermediate product is drained and filtered in a circulating water bath and then is subjected to vacuum drying, and the tissue engineering scaffold with the porosity up to 68-74.0%, the bubble hole size of 20-200 microns and the internal intercommunication channel size of about 20-200 microns and made from a porous material can be obtained. The preparation method can complete fiber crosslinking and fusion between in a low temperature state without solvents, crosslinking agents and the like, and cytotoxicity is not produced.

The invention relates to a preparation method for preparing a polylactic acid tissue engineering scaffold. According to the method, 25-40% of polylactic acid, 30-45% of polyoxymethylene and 25-40% of sodium bicarbonate are mixed up to prepare a mixed solution and then the mixed solution is subjected to spinning to obtain polylactic acid electrospun nanofibers. The nanofibers are processed in supercritical carbon dioxide. Through controlling the processing pressure and the processing temperature, an intermediate product is obtained. The obtained intermediate product is subjected to leaching in the circulating water bath and then drying in vacuum, and then the tissue engineering scaffold is obtained. The obtained tissue engineering scaffold is made of porous materials, wherein the porosity of the tissue engineering scaffold is 68 to 74.0% and the cell size of the tissue engineering scaffold is 20 to 200 microns. The dimension of the inner communicating channel of the tissue engineering scaffold is about 20 to 200 microns. According to the technical scheme of the preparation method in the invention, fibers can be cross-linked and fused at a relatively low temperature without any solvent or cross-linking agent. Meanwhile, the generation of cytotoxicity is avoided.

The invention relates to a preparation method of a polycaprolactone tissue engineering scaffold. The method includes preparing 25-40% of polycaprolactone, 30-45% of polyoxyethylene and 25-40% of sodium bicarbonate into mixed solution, performing spinning to obtain polycaprolactone nanofibers, treating the nanofibers in supercritical CO2 to obtain an intermediate product by means of controlling treatment pressure and treatment temperature, and subjecting the obtained intermediate product to percolation in circulating water bath prior to vacuum drying to obtain the tissue engineering scaffold made of a porous material with the porosity reaching 68-74.0%, the cell size being 20-200 microns and the size of internally mutually communicated channels being about 20-200 microns. The preparation method can finish inter-fiber crosslinking and fusion at low temperature without solvent, cross-linking agent and the like, and cytotoxicity is avoided.

The present application provides: a polypeptide characterized by having an ability of penetrating into a cell and the structure represented by Formula (I)wherein n is a number of 2 to 20; R1 and R2 may independently represent a C1-C4 alkyl group or may bind to each other to form a ring; R3 represents a C1-C10 primary aminoalkyl group; R4 represents a hydrogen atom or a C1-C10 hydrocarbon group; the “n” number of R1, R2, R3, and R4 may independently be the same with or different from each other; and the N-terminus and the C-terminus may or may not be modified independently; and a cell-invasive composition comprising the polypeptide and a substance of interest.